Abstract
Acute myelogenous leukemia (AML) is a difficult disease to treat, and better treatments are needed. Molecular targeted therapy represents a novel therapeutic approach. The FLT3 tyrosine kinase receptor is mutated in approximately one-fourth to one-third of patients with AML. Normally, binding of FLT3 ligand to the FLT3 receptor leads to phosphorylation of tyrosine residues and activation of the receptor. This in turn leads to induction of intracellular signaling pathways essential to regulation of cell proliferation and apoptosis. Two classes of FLT3 activating mutations have been identified in AML patients: internal tandem duplications (ITDS) and point mutations in the activating loop of the kinase domain. Both mutations result in constitutive FLT3 tyrosine kinase activity and lead to transformation of hematopoietic cell lines in vivo and in vitro. FLT3 ITDs are also an independent poor prognostic factor for overall survival and disease free survival in patients with AML. Therefore, targeting FLT3 mutations represents a potential therapeutic target for AML. This review will discuss the biology and clinical significance of FLT3 and FLT3 mutations in cell growth and signaling. In addition, I will discuss some of the novel FLT3 inhibitors which are entering clinical trials for AML.
Keywords: acute myelogenous leukemia, flt mutations, targeted therapy, flt inhibitors
Current Pharmaceutical Design
Title: FLT3 and Acute Myelogenous Leukemia: Biology, Clinical Significance and Therapeutic Applications
Volume: 11 Issue: 26
Author(s): A. S. Advani
Affiliation:
Keywords: acute myelogenous leukemia, flt mutations, targeted therapy, flt inhibitors
Abstract: Acute myelogenous leukemia (AML) is a difficult disease to treat, and better treatments are needed. Molecular targeted therapy represents a novel therapeutic approach. The FLT3 tyrosine kinase receptor is mutated in approximately one-fourth to one-third of patients with AML. Normally, binding of FLT3 ligand to the FLT3 receptor leads to phosphorylation of tyrosine residues and activation of the receptor. This in turn leads to induction of intracellular signaling pathways essential to regulation of cell proliferation and apoptosis. Two classes of FLT3 activating mutations have been identified in AML patients: internal tandem duplications (ITDS) and point mutations in the activating loop of the kinase domain. Both mutations result in constitutive FLT3 tyrosine kinase activity and lead to transformation of hematopoietic cell lines in vivo and in vitro. FLT3 ITDs are also an independent poor prognostic factor for overall survival and disease free survival in patients with AML. Therefore, targeting FLT3 mutations represents a potential therapeutic target for AML. This review will discuss the biology and clinical significance of FLT3 and FLT3 mutations in cell growth and signaling. In addition, I will discuss some of the novel FLT3 inhibitors which are entering clinical trials for AML.
Export Options
About this article
Cite this article as:
Advani S. A., FLT3 and Acute Myelogenous Leukemia: Biology, Clinical Significance and Therapeutic Applications, Current Pharmaceutical Design 2005; 11 (26) . https://dx.doi.org/10.2174/138161205774370807
DOI https://dx.doi.org/10.2174/138161205774370807 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Down Regulation of Differentiated Embryo-Chondrocyte Expressed Gene 1 is Related to the Decrease of Osteogenic Capacity
Current Drug Targets Paclitaxel Loaded Nanoliposomes in Thermosensitive Hydrogel: A Dual Approach for Sustained and Localized Delivery
Anti-Cancer Agents in Medicinal Chemistry Gut Epithelial Lining Makes the First Move
Current Immunology Reviews (Discontinued) Immunity to Tumour Antigens
Current Pharmaceutical Design A Fast and Efficient Chemiluminescence Method for Determination and Pharmacokinetic Study of Paclitaxel in Rat Plasma
Current Pharmaceutical Analysis In Vivo Tumor Secretion Probing Via Ultrafiltration and Tissue Chamber:Implication for Anti-Cancer Drugs Targeting Secretome
Recent Patents on Anti-Cancer Drug Discovery Titanocene Y - Transport and Targeting of an Anticancer Drug Candidate
Letters in Drug Design & Discovery Chemokines as Pharmacological Targets
Mini-Reviews in Medicinal Chemistry Bioactivity and Pharmacological Actions of Carbon Monoxide-Releasing Molecules
Current Pharmaceutical Design Challenges and Successes Using Nanomedicines for Aerosol Delivery to the Airways
Current Gene Therapy Gene Therapy (Part I)
Current Gene Therapy Tubulin Inhibitors: A Patent Survey
Recent Patents on Anti-Cancer Drug Discovery Methods of Preparation of Multifunctional Microbubbles and their In Vitro / In Vivo Assessment of Stability, Functional and Structural Properties
Current Pharmaceutical Design Role of CYP2E1 in Mitochondrial Dysfunction and Hepatic Injury by Alcohol and Non-Alcoholic Substances
Current Molecular Pharmacology Possible Considerations for the Management of Turcot’s Syndrome?
Current Cancer Therapy Reviews Characterization of Molecular and Functional Alterations of Tumor Endothelial Cells to Design Anti-Angiogenic Strategies
Current Vascular Pharmacology An Overview of Cardenolides in Digitalis - More Than a Cardiotonic Compound
Current Pharmaceutical Design Regulation of LDLR, Bcl-2 and FASN Expressions by Oxidized Low Density Lipoprotein in Estrogen Receptor Positive Breast Cancer Cells
Current Pharmacogenomics and Personalized Medicine Ulipristal Acetate (Esmya) in the Management of Heavy Menstrual Bleeding Associated with Fibroids: A Case Series
Current Women`s Health Reviews Hypoxia-Inducible Factor 1 in Tumor Radioresistance
Current Signal Transduction Therapy